|
Title
|
Publication Date
|
Price
|
Relevance
|
|
Mitsubishi Tanabe Pharma Corporation: PharmaVitae Model
|
Jan 2009 |
£3,605 |
100% |
|
Mitsubishi Tanabe Pharma Corporation-Detailed Product Pipeline
|
Mar 2011 |
£475 |
99% |
|
Mitsubishi Tanabe Pharma Corp.: PharmaVitae Profile
|
Apr 2011 |
£3,605 |
99% |
|
Mitsubishi Tanabe Pharma Corporation-Therapeutic Competitors Report
|
Mar 2011 |
£220 |
99% |
Mitsubishi Tanabe Pharma
Pipeline, Products, Performance, Potential
|
Jan 2008 |
£595 |
98% |
|
Mitsubishi Tanabe Pharma Corporation: PharmaVitae Profile
|
Jun 2010 |
£3,605 |
98% |
|
Mitsubishi Tanabe Pharma Corporation-Deals & Alliances Report
|
Mar 2011 |
£380 |
98% |
Mitsubishi Tanabe Pharma Corporation – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
97% |
|
Biotechnology in Asia-Pacific
|
Sep 2011 |
£160 |
91% |
|
Biotechnology in Japan
|
Sep 2011 |
£160 |
90% |
|
The Pharmaceutical Market: Japan
|
Oct 2011 |
£595 |
87% |
MediciNova, Inc. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
84% |
|
The Japanese Pharmaceutical Market 20082023
|
Oct 2008 |
£1,499 |
83% |
|
Generics in Japan
|
Nov 2009 |
£1,825 |
81% |
Vertex Pharmaceuticals Incorporated – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
81% |
|
M&A trends in Pharma
|
Oct 2008 |
£7,210 |
80% |
Type 2 Diabetes - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
80% |
|
Inflammatory Bowel Disease Therapeutics
|
Apr 2010 |
£2,500 |
78% |
Hyperphosphatemia Global Clinical Trials Review
Q2, 2011
|
Jun 2011 |
£630 |
78% |
World Diabetes Drug Market
2011-2021
|
Mar 2011 |
£1,499 |
78% |
|
Ono Pharmaceutical: Pipeline, Products, Performance, Potential
|
Jan 2012 |
£595 |
77% |
Vertex Pharmaceuticals Incorporated - Pharmaceuticals & Healthcare
Deals and Alliances Profile
|
Jul 2009 |
£160 |
77% |
|
Partnering Agreements with Mitsubishi Tanabe 2010
|
Jan 2010 |
£630 |
77% |
Chronic Kidney Disease (CKD) Therapeutics
Pipeline Assessment and Market Forecasts to 2018
|
Sep 2011 |
£2,215 |
77% |
Acute Ischemic Stroke (AIS) Therapeutics
Pipeline Assessment and Market Forecasts to 2018
|
Sep 2011 |
£2,215 |
76% |
Diabetes - Pipeline Review
H2 2011
|
Oct 2011 |
£315 |
76% |
Top 100 Pharmaceutical Manufacturers Industry Analysis - Worldwide
Business Performance Analysis
|
Aug 2011 |
£950 |
75% |
Cancer Pain Global Clinical Trials Review
Q1, 2011
|
Feb 2011 |
£630 |
75% |
Rheumatoid Arthritis
Pipeline Assessment and Market Forecasts to 2017
|
Nov 2010 |
£1,265 |
75% |
Dyslipidemia - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
75% |
